AstraZeneca earnings hit by waning cholesterol drug sales
July 28, 2016 at 02:13 AM EDT
LONDON, July 28 (Reuters) - Generic competition to cholesterol fighter Crestor in the key U.S. market hit second-quarter earnings at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes.
